RecruitingNCT06308510

Detection of Aneuploidy in Cell Free DNA to Improve the Sensitivity of Diagnostic Peritoneal Lavage in Gastric Cancer

Sponsor

Erasmus Medical Center

Enrollment

63 participants

Start Date

Dec 17, 2024

Study Type

OBSERVATIONAL

Conditions

Gastric Cancer

Summary

Aneuploidy may be used as a more sensitive diagnostic tool to detect peritoneal metastasis compared to conventional cytology and imaging techniques. Our aim is to establish whether aneuploidy as detected in cfDNA (as a measure for ctDNA) in PLF of patients with GC may hold value as an additional staging and tumor evaluation method in GC patients.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study looks at whether testing for cancer DNA floating in fluid taken from the belly during surgery (peritoneal lavage) can help detect early spread of gastric (stomach) cancer that might be missed by standard methods. It also includes a non-cancer comparison group of patients having routine abdominal surgery. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with stomach (gastric) cancer, OR - You are having a planned laparoscopic (keyhole) abdominal surgery for a non-cancer reason such as gallbladder disease or weight-loss surgery - You are able to provide written informed consent **You may NOT be eligible if...** - You have difficulty understanding or communicating due to language barriers, dementia, or altered mental state - You have an active infection or inflammation (non-cancer group) - You have had another cancer in the past 5 years (non-cancer group) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.